Idera Pharmaceuticals (IDRA)
Idera Pharmaceuticals Fundamental Score: 5.00
View IDRA Fundamental Score with YCharts Pro.
Access these YCharts Pro features:
Export any data you want
Save any chart as an image
Utilize advanced screener power
View 30 years of financial history
over 90 advanced calculations
Enjoy an advertising free experience
IDRA Fundamental Score Rankings
| Overall | 33rd percentile | 2846 of 4269 |
| Sector | 45th percentile | 246 of 454 in Healthcare |
| Industry | 69th percentile | 41 of 133 in Biotechnology |
IDRA Fundamental Score Range, Past 5 Years
| Minimum | 3.00 | Jun 2007 |
| Maximum | 6.00 | Dec 2008 |
| Average | 5.20 |
About Fundamental Score
The fundamental score is YCharts proprietary score of how strong a company's fundamentals are. It ranges from 1 to 10, with 10 being the strongest. The ten tests are as follows (score one point for each test the company passes):
1) EPS Growth > 0
2) Revenue Growth > 0
3) Five Year Average ROE > 5%
4) 10 Year Minimum Gross Margin > 0
5) Book Value Per Share Growth > 0
6) Current Ratio > 1
7) Debt to Equity Ratio < 13
8) 10 Year Average Cash Flow > 0
9) Long Term Debt < 5 x Net Income
10) Uninterrupted dividend payments as far back as we have data
(unless otherwise noted, growth rates are calculated for 10 years or the life of the stock, whichever is shorter)
Further details can be found in our support center article about the fundamental score.
Learn More
You may also be interested in these IDRA related companies
IDRA News
Idera Pharmaceuticals, Inc. (IDRA) Posts Narrower than Expected Q1 Loss
May 09, 7:49AM Street Insider
May 09, 7:49AM Street Insider
Idera Pharmaceuticals Announces Efficacy Data for IMO-8400 in Preclinical Models of Lupus and Psoriasis
May 07, 7:00AM Business Wire
May 07, 7:00AM Business Wire
Idera Pharmaceuticals Announces Presentation of Preclinical Data of IMO-8400 in Both Lupus and Psoriasis Models
May 01, 8:00AM Business Wire
May 01, 8:00AM Business Wire
Idera Pharmaceuticals to Present at the 11th Annual Needham Healthcare Conference
Mar 29, 8:30AM Business Wire
Mar 29, 8:30AM Business Wire
$IDRA http://stks.co/36xd tiny #BIOTECH with a nice round bottom on LT chart - $IDRA
about 63 days ago by LTbioinvestor
about 63 days ago by LTbioinvestor
Idera Pharmaceuticals Reports Fourth Quarter and Full Year 2011 Financial Results and Provides Pipeline Update
Mar 14, 8:30AM Business Wire
Mar 14, 8:30AM Business Wire
Idera Pharmaceuticals to Present at Cowen’s 32nd Annual Healthcare Conference
Feb 28, 9:05AM Business Wire
Feb 28, 9:05AM Business Wire
Idera Pharmaceuticals to Present at Cancer Immunotherapy Summit on February 28th
Feb 27, 9:05AM Business Wire
Feb 27, 9:05AM Business Wire
Idera Pharmaceuticals Announces Retirement of Dr. James B. Wyngaarden as a Member of the Board of Directors
Feb 17, 9:05AM Business Wire
Feb 17, 9:05AM Business Wire
$IDRA making a move before BioCEO presentation tomorrow morning. Glad I picked some up cheap last week.
about 106 days ago by illinijill
about 106 days ago by illinijill
$IDRA http://stks.co/2MeF tiny BIO name, chart looks ready for a move, on watch for a possible speculative buy - $IDRA
about 107 days ago by LTbioinvestor
about 107 days ago by LTbioinvestor
CORRECTING and REPLACING Idera Pharmaceuticals to Present at BIO CEO Conference February 13th, 2012
Feb 06, 10:23AM Business Wire
Feb 06, 10:23AM Business Wire
Idera Pharmaceuticals presents positive data on IMO-4200 preclinical models
Dec 13, 4:20PM theflyonthewall.com
Dec 13, 4:20PM theflyonthewall.com
Idera Pharmaceuticals files to sell 8.43M of common stock for holders
Dec 09, 4:16PM theflyonthewall.com
Dec 09, 4:16PM theflyonthewall.com
Idera Pharmaceuticals (IDRA) Receives FDA Approval to Proceed with Phase 2 Trials of IMO-3100
Dec 01, 8:40AM Street Insider
Dec 01, 8:40AM Street Insider
Idera Pharmaceuticals announces FDA authorization for Phase 2 IMO-3100 trial
Dec 01, 8:37AM FlyOnTheWall
Dec 01, 8:37AM FlyOnTheWall
Idera Pharmaceuticals Regains Global Rights to IMO-2055 in Oncology from Merck KGaA
Nov 30, 8:33AM Benzinga
Nov 30, 8:33AM Benzinga
Idera Pharma (IDRA) Reports Encouraging Preclinical Data for Novel GSO Technology
Nov 15, 8:45AM Street Insider
Nov 15, 8:45AM Street Insider
$IDRA great pharma name w/ tremendous potential. Hidden Gem if there ever was 1. Could be a 10-bagger next year same time. Very strong buy
about 260 days ago by pumpndumphunter
about 260 days ago by pumpndumphunter
$IDRA
Idera Reports Clinical Hold on Proposed Phase 2 Clinical Trial of IMO-3100
about 314 days ago by Benzinga
about 314 days ago by Benzinga
Idera Pharma $IDRA reports clinical hold on proposed Phase 2 trial of IMO-3100
about 314 days ago by Street_Insider
about 314 days ago by Street_Insider
Idera $IDRA says Merck won't conduct further development on IMO-2055, will complete ongoing Phase 2 with Erbitux; stock halted
about 328 days ago by Street_Insider
about 328 days ago by Street_Insider
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| IDRA | 1.00 | -0.02 | -1.96% | 27.64M |
| IDN | 1.64 | -0.09 | -5.07% | 47.44M |
| IDIX | 9.41 | -0.27 | -2.79% | 1.041B |
| IDI | 1.85 | -0.03 | -1.60% | 38.59M |
| IDCC | 25.28 | +0.14 | +0.56% | 1.134B |
| IDA | 39.30 | +0.17 | +0.43% | 1.955B |
| ICUI | 52.22 | +0.21 | +0.40% | 722.94M |
| ICS | 15.36 | +0.07 | +0.46% | |
| ICON | 15.86 | +0.38 | +2.45% | 1.123B |
| ICLR | 21.90 | -0.03 | -0.14% | 1.319B |
